Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy

Annals of Oncology

Volumn 17, Issue 1, 2006, Pages 131-134

  Ghavamzadeh, A ^a   Alimoghaddam, K ^a   Ghaffari, S H ^a   Rostami, S ^a   Jahani, M ^a   Hosseini, R ^a   Mossavi, A ^a   Baybordi, E ^a   Khodabadeh, A ^a   Iravani, M ^a   Bahar, B ^a   Mortazavi, Y ^b   Totonchi, M ^a   Aghdami, N ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

APL; Arsenic trioxide; Minimal residual disease

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; RETINOIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER SURVIVAL; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 29844442869     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj019     Document Type: Article

References (27)

1. Tallman MS, Andersen JW, Schiffer CA et al. All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 100: 4298-4302.
2. Fenaux P, Castaigne S, Dombret H et al. All transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: A pilot study on 26 cases. Blood 1992; 80: 2176-2181.
3. Ohno R, Yoshida H, Fukutani H et al. Multi-institutional study of all-trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia 1993; 7: 1722-1728.
4. Kanamaru A, Takemoto Y, Tanimoto M et al. Alltrans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 1995; 85: 1202-1206.
5. Mandelli F, Diverio D, Awisati G et al. Molecular remission in PML-RAR positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997; 90: 1014-1021.
6. Sanz MA, Martin G, Rayon C et al. A modified AIDA protocol with anthracycline based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR-positive acute promyelocytic leukemia. Blood 1999; 94: 3015-3021.
7. Fenaux P, Le Deley MC, Castaigne S et al. Alltrans retinoic acid in newly diagnosed acute promyelocytic leukemia: Results of a multicenter randomized trial. Blood 1993; 82: 3241-3249.
8. Tallman MS, Andersen JW, Schiffer CA et al. Alltrans retinoid acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021-1028.
9. Burnett AK, Grimwade D, Solomon E et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Results of the randomized MRC trial. Blood 1999; 93: 4131-4143.
10. Fenaux P, Chevret S, Guerci A et al. Long-term follow-up confirms the benefits of all-trans retinoic acid in acute promyelocytic leukemia. Leukemia 2000; 14: 1371-1377.
11. Fenaux P, Chastang G, Chevret S et al. A randomized comparison of all-trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 1192-1200.
12. Sun H, Ma L, Hu X, Zhang T. Treatment of acute promyelocytic leukemia by Ailing-1 therapy with use of syndrome differentiation of traditional Chinese medicine. Chin J Comb Trad Chin Med West Med 1992; 12: 170-172.
13. Zhang P, Wang S, Hu X. Arsenic trioxide treated cases of acute promyelocytic leukemia. Chin Hematol 1996; 17: 58-62.
14. Shen Z, Chen G, Ni J. Use of arsenic trioxide in the treatment of APL, clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
15. Niu C, Yan H, Yu T et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315-3324.
16. Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852-3860.
17. Au WY, Lie AKW, Chim CS et al. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for treatment of relapsed acute promyelocytic leukaemia. Ann Oncol 2003; 14: 752-758.
18. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759-767.
19. Huang ME, Ye YC, Chen SR et al. Use of alltrans retinoic acid in the treatment of APL. Blood 1988; 72: 567-572.
20. Chen ZX, Xue YQ, Zhang R et al. A clinical and experimental study on all-trans retinoic acid treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413-1419.
21. Castaigne S, Chomienne C, Daniel MT et al. Alltrans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76: 1704-1709.
22. Castaigne S, Chomienne C, Daniel MT et al. Retinoic acids in the treatment of acute promyelocytic leukemia. Nouv Rev Fr Hematol 1990; 32: 36-38.
23. Grimwade D, Howe K, Langabeer S et al. Minimal residual disease detection in acute promyelocytic leukemia reverse transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse. Leukemia 1996; 10: 61-66.
24. Diverio D, Rossi V, Avvisati G et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RAR-alpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. Blood 1998; 92: 784-789.
25. Lo Coco F, Diverio D, Avvisati G et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225-2229.
26. Hoffman R, Haddad N, Sahar D et al. High-dose cytarabine therapy induces a molecular remission in APL patients who failed to achieve a complete response following treatment with ATRA and anthracyclines. Blood 1998; 92: 2517 (Abstr).
27. Lo Coco F, Diverio D, Falini B et al. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999; 94: 12-22.